Earnings summaries and quarterly performance for CORCEPT THERAPEUTICS.
Executive leadership at CORCEPT THERAPEUTICS.
Joseph K. Belanoff, M.D.
Detailed
Chief Executive Officer and President
CEO
Atabak Mokari
Detailed
Chief Financial Officer and Treasurer
Charles Robb
Detailed
Chief Business Officer and Secretary
Hazel Hunt, Ph.D.
Detailed
Chief Scientific Officer
Joseph D. Lyon
Detailed
Chief Accounting and Technology Officer
Sean Maduck
Detailed
President, Corcept Endocrinology
William Guyer, Pharm.D.
Detailed
Chief Development Officer
Board of directors at CORCEPT THERAPEUTICS.
Research analysts who have asked questions during CORCEPT THERAPEUTICS earnings calls.
David Amsellem
Piper Sandler Companies
4 questions for CORT
Also covers: ABBV, ALKS, AMGN +27 more
Joon Lee
Truist Securities
3 questions for CORT
Also covers: ADVM, AXSM, CNM +14 more
Swayampakula Ramakanth
H.C. Wainwright & Co.
3 questions for CORT
Also covers: ABSI, BSEM, CGEN +24 more
Edward Nash
Canaccord Genuity
2 questions for CORT
Also covers: GLMD
Asim Rana
Truist Securities
1 question for CORT
Also covers: AXSM, CPRX, SAGE +2 more
Matthew Kaplan
Ladenburg Thalmann
1 question for CORT
Also covers: ARDX, AXSM, ELDN +8 more
Ramakanth Swayampakula
H.C. Wainwright & Co., LLC
1 question for CORT
Also covers: AEMD, HUMA, IPA +1 more
Recent press releases and 8-K filings for CORT.
Corcept Therapeutics Reports Q3 2025 Results and Updates Guidance
CORT
Earnings
Guidance Update
Product Launch
- Corcept Therapeutics reported Q3 2025 revenue of $207.6 million and net income of $19.7 million, with $524 million in cash and investments as of September 30th, 2025.
- The company updated its 2025 revenue guidance to $800-$850 million.
- Key PDUFA dates for relacorilant include December 30, 2025, for hypercortisolism and July 11, 2026, for platinum-resistant ovarian cancer.
- Corcept is awaiting a decision in its patent litigation against Teva Pharmaceuticals, which could prevent Teva from marketing a generic Korlym until 2037 if Corcept wins.
- The company is expanding its pharmacy network, transitioning to a new primary vendor in Q4 2025 and planning to add more in early 2026, anticipating $3-$5 billion in annual revenue from relacorilant in hypercortisolism alone within three to five years.
Nov 4, 2025, 10:00 PM
Corcept Therapeutics Reports Q3 2025 Financial Results and Updates 2025 Revenue Guidance
CORT
Earnings
Guidance Update
Product Launch
- Corcept Therapeutics reported Q3 2025 revenue of $207.6 million and net income of $19.7 million, with cash and investments totaling $524 million as of September 30, 2025.
- The company modified its 2025 revenue guidance to $800 million-$850 million.
- Key regulatory milestones include PDUFA dates for Relacorilant for hypercortisolism on December 30, 2025, and for platinum-resistant ovarian cancer on July 11, 2026.
- Operational updates include a 42.5% increase in Korlym tablet shipments compared to the prior year period, a transition to a new pharmacy in Q4 2025 to address capacity constraints, and plans to add more pharmacies in early 2026.
- The company expects R&D expenditures in 2026 to be similar to 2025, while SG&A expenses are projected to increase due to investments for Relacorilant launches.
Nov 4, 2025, 10:00 PM
Corcept Therapeutics Announces Q3 2025 Results and Provides Business Update
CORT
Earnings
Guidance Update
New Projects/Investments
- Corcept Therapeutics reported Q3 2025 revenue of $207.6 million and net income of $19.7 million, and updated its 2025 revenue guidance to $800-$850 million.
- The company anticipates FDA approval for relacorilant in hypercortisolism by its December 30, 2025 PDUFA date, and for platinum-resistant ovarian cancer by July 11, 2026.
- Corcept is significantly expanding its oncology development, initiating new Phase 2 studies for relacorilant in various gynecological and pancreatic cancers, and a Phase 1b study for nenocorilant in solid tumors.
- A decision is expected soon on the appeal of the patent litigation against Teva Pharmaceuticals regarding Korlym.
- To address capacity issues and prepare for future growth, Corcept is transitioning to a new pharmacy vendor and plans to onboard additional specialty pharmacies.
Nov 4, 2025, 10:00 PM
Corcept Therapeutics Announces Q3 2025 Financial Results and Corporate Update
CORT
Earnings
Guidance Update
Share Buyback
- Corcept Therapeutics reported revenue of $207.6 million for Q3 2025, an increase from $182.5 million in Q3 2024, while net income decreased to $19.7 million from $47.2 million in the same period last year.
- The company modified its 2025 revenue guidance to $800 – $850 million and is adding new specialty pharmacies to address capacity constraints and meet increasing demand.
- Key clinical development milestones include a PDUFA date of December 30, 2025, for the relacorilant New Drug Application (NDA) in hypercortisolism and July 11, 2026, for the relacorilant NDA in platinum-resistant ovarian cancer.
- As of September 30, 2025, cash and investments totaled $524.2 million, reflecting a $50.6 million common stock acquisition during the quarter through the company's stock repurchase program.
Nov 4, 2025, 9:08 PM
Corcept Therapeutics Announces Third Quarter Financial Results and Updated 2025 Guidance
CORT
Earnings
Guidance Update
New Projects/Investments
- Corcept Therapeutics reported Q3 2025 revenue of $207.6 million, an increase from $182.5 million in Q3 2024, while net income decreased to $19.7 million from $47.2 million in the prior year period.
- The company modified its 2025 revenue guidance to $800 – $850 million.
- As of September 30, 2025, Corcept held $524.2 million in cash and investments and repurchased $50.6 million of common stock during the third quarter.
- Key regulatory milestones include a PDUFA date of December 30, 2025, for relacorilant in hypercortisolism and July 11, 2026, for relacorilant in platinum-resistant ovarian cancer.
- Corcept is expanding its oncology development programs to include new studies in earlier-stage ovarian, endometrial, cervical, and pancreatic cancers, and a broad range of solid tumors.
Nov 4, 2025, 9:05 PM
Corcept Presents Positive Relacorilant Data at ESMO 2025
CORT
New Projects/Investments
- Corcept Therapeutics presented new updated data from its Phase III ROSELLA study at the 2025 European Society for Medical Oncology (ESMO) annual congress.
- The data confirmed that relacorilant plus nab-paclitaxel improves progression-free survival and overall survival in patients with platinum-resistant ovarian cancer.
- This benefit was observed even in patients who had progressed during or after a PARP inhibitor, a group with a particularly unfavorable prognosis, and did not require biomarker selection.
- Corcept is also expanding its BELLA study to include three groups: platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and endometrial cancer.
Oct 20, 2025, 9:00 PM
Corcept Presents New Relacorilant Data at ESMO 2025
CORT
New Projects/Investments
- Corcept Therapeutics presented new data from its pivotal Phase 3 ROSELLA study of relacorilant plus nab-paclitaxel at the ESMO 2025 Annual Meeting.
- The data reconfirms that relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, including those previously treated with a PARP inhibitor, without the need for biomarker selection.
- Corcept is expanding its BELLA study to include three arms: platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and cervical cancer.
Oct 20, 2025, 8:59 PM
Corcept presents late-breaking data at ESMO 2025
CORT
Product Launch
New Projects/Investments
- Corcept Therapeutics presented new late-breaking data from its pivotal Phase III ROSELLA trial at ESMO 2025, demonstrating that relacorilant plus nab-paclitaxel improved progression-free survival and overall survival in patients with platinum-resistant ovarian cancer, including those previously treated with PARP inhibitors.
- The company also announced the expansion of its BELLA trial to include three study groups: platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and endometrial cancer.
Oct 20, 2025, 8:59 PM
Corcept Therapeutics Presents ESMO 2025 Relacorilant Data and BELLA Study Expansion
CORT
New Projects/Investments
Product Launch
- Corcept Therapeutics presented new Phase 3 ROSELLA study data at ESMO 2025, demonstrating Relacorilant plus nab-Paclitaxel showed consistent efficacy and a progression-free survival (PFS) benefit in patients with platinum-resistant ovarian cancer, including those previously treated with PARP inhibitors.
- The combination therapy resulted in a 30% reduced risk of disease progression and a 31% reduced risk of death in an interim overall survival analysis for platinum-resistant ovarian cancer patients.
- Corcept also announced the expansion of its Phase 2 BELLA study to include three arms: platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, and endometrial cancer, with initial results anticipated in late 2026.
- The FDA has set a PDUFA date of July 11, 2026, for Relacorilant for the treatment of patients with platinum-resistant ovarian cancer.
Oct 20, 2025, 8:58 PM
Corcept Presents Positive Relacorilant Data at ESMO 2025 and Announces Trial Expansion
CORT
Product Launch
New Projects/Investments
- Corcept Therapeutics presented new data at ESMO 2025 from its pivotal Phase 3 ROSELLA trial, demonstrating that relacorilant combined with nab-paclitaxel improved progression-free survival and overall survival in patients with platinum-resistant ovarian cancer, particularly those previously treated with PARP inhibitors.
- In PARP inhibitor-treated subgroups, relacorilant showed a consistent PFS benefit (hazard ratio: 0.60; p-value: 0.0035) with a median PFS of 7.36 months, and was well-tolerated. The ROSELLA trial previously reported a 30% reduction in disease progression risk and a 31% reduction in the risk of death.
- Corcept has expanded its Phase 2 BELLA trial to include platinum-sensitive ovarian cancer and endometrial cancer, with initial results expected by the end of 2026.
- The FDA has set PDUFA dates for relacorilant: December 30, 2025, for hypercortisolism and July 11, 2026, for platinum-resistant ovarian cancer. Corcept also submitted a Marketing Authorization Application to the EMA for relacorilant in platinum-resistant ovarian cancer.
Oct 20, 2025, 8:58 PM
Quarterly earnings call transcripts for CORCEPT THERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more